CAS 1253641-65-4

Formule : C30H25Cl2F3N4OS

InChI : InChI=1S/C30H25Cl2F3N4OS/c1-2-23-27(29(40)37-38-16-4-3-5-17-38)36-39(25-14-11-21(31)18-24(25)32)28(23)26-15-13-22(41-26)12-8-19-6-9-20(10-7-19)30(33,34)35/h6-7,9-11,13-15,18H,2-5,16-17H2,1H3,(H,37,40)

Code InChI : VQOCBFYUDSBDCZ-UHFFFAOYSA-N

SMILES : CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(S4)C#CC5=CC=C(C=C5)C(F)(F)F

CB1 antagonist 4

CAS : 1253641-65-4

CB1 antagonist 4

Formule : C₃₀H₂₅Cl₂F₃N₄OS

Degré de pureté : 98.5%

Masse moléculaire : 617.51

Ref: 54-BUP09789

CB1 antagonist 4

CAS : 1253641-65-4

Formule : C₃₀H₂₅Cl₂F₃N₄OS

Degré de pureté : 99.00%

Masse moléculaire : 617.5119

Ref: IN-DA01KYQH

CB1 antagonist 4

CAS : 1253641-65-4

TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes.

Formule : C₃₀H₂₅Cl₂F₃N₄OS

Degré de pureté : 98.97%

Couleur et forme : White Solid

Masse moléculaire : 617.51

Ref: TM-T8511

TM38837

CAS : 1253641-65-4

TM38837 is a pyrimidine compound that is being developed as a treatment for metabolic disorders. It has been shown to be potent inducers of toll-like receptor 4, cox-2 inhibitory activity, and autophagy. TM38837 has also been shown to inhibit the activation of the cb2 receptor and body mass index in vitro assays. This drug has photochemical properties that are useful for its pharmacokinetic properties. TM38837 is metabolized by trifluoroacetic acid (TFA) and excreted by the kidneys into the urine with a half-life of about 3 hours.

Formule : C₃₀H₂₅Cl₂F₃N₄OS

Degré de pureté : Min. 95%

Masse moléculaire : 617.5 g/mol

Ref: 3D-DAC64165